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Abstract 
Rationale: Black box warnings for young adults under the age of 25 years indicate that 
antidepressants may increase risk of suicide. While underlying mechanisms for age-related 
treatment effects remain unclear, vagally mediated cardiovascular function may play a key role. 
Decreased heart rate (HR) and an increase in its variability (HRV) improve ones capacity to adapt 
to environmental stress and attenuate risk for suicide. Objectives: Using a double blind, 
randomized, placebo-controlled, crossover, mixed experimental study, we examine whether a 
single-dose of escitalopram (20mg) attenuates cardiovascular responses to stress under 
experimental conditions, and determine whether age moderates these effects. Methods: Forty-four 
healthy females received a single dose of escitalopram (20mg) and placebo treatment separated by a 
one-week interval (> 5 half-lives). HR and high frequency HRV (HF HRV n.u.; 0.15–0.40 Hz) were 
measured during resting state and stress. Results: While escitalopram attenuated the increase in HR 
and increased HF HRV, these moderate to large effects were only significant in participants over 25 
years of age. No beneficial cardiovascular effects of escitalopram were observed in those under the 
age of 25. Conclusions: Maturational differences in development of the prefrontal cortex – a critical 
region in the central network of autonomic control – may underpin these differential findings. This 
study provides a theoretical framework on which future research on treatment-emergent suicidality 
in clinical populations could be based.  
 
Keywords: heart rate, heart rate variability, escitalopram, SSRI, antidepressant, stress, age, young 
adults, maturation 
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Introduction 
There is a growing body of evidence to suggest that adolescents and young people 
differentially respond to antidepressant treatment compared to more mature adults within the acute 
depressive episode (Barbui et al. 2009; Gibbons et al. 2012; Hammad et al. 2006a; Stone et al. 
2009a). While underlying mechanisms for the differential treatment effects of age remain unclear 
(including an increase in suicidality), vagally mediated cardiac function may play a key role. A 
large body of literature suggests that the cardiovascular system may play a role in mental and 
physical health (see Kemp and Quintana 2013 for review). Most relevant for the current study is the 
link to psychological flexibility (Kashdan and Rottenberg 2010), the role of the vagal nerve in the 
inhibition of sympathetic nervous system responses to environmental stress (Thayer et al. 2009) and 
epidemiological findings reporting an association between vagally mediated cardiovascular function 
and suicidality (Åberg et al. 2013; Lemogne et al. 2011). Here we examined whether age-dependent 
differences in responses to acute administration of escitalopram – a first-line treatment option for 
moderate to severe major depressive disorder in adolescents (Ahn and Patkar 2011) – may be 
underpinned by differential cardiovascular responses; this is the hypothesis of the present study. We 
conducted a double blind, randomized, placebo-controlled, crossover, mixed experimental study on 
a well-characterized sample of healthy participants to avoid confounds associated with study of 
clinical samples. Our study lays an important theoretical framework for better understanding 
differential age-related responses to the early effects of antidepressant medication. 
Vagally mediated cardiovascular function – including heart rate (HR) and its variability 
(HRV) – reflects the function of the central autonomic network (CAN) including the PFC, 
cingulate, insula, amygdala and brainstem structures (Thayer et al. 2009). The inhibitory role of the 
PFC is critical for overriding automatic and prepotent responses associated with subcortical 
structures such as the amygdala and medullary cardioacceleratory circuits (Thayer et al. 2009). 
However, adolescence and young adulthood is a developmental period in which the prefrontal 
cortex is often unable to provide sufficient top-down control over subcortical structures (Casey et al. 
2008), leading to impulsive behavior and, in clinical populations, suicidality, especially in the face 
of emotional stress. Recent epidemiological studies have highlighted a role for vagally mediated 
cardiovascular function in suicidal behaviours. One study on more than 320,000 participants 
reported that an increase in heart rate by 10 additional beats per minute increases the risk of 
completed suicide by 19% to 37% over a follow-up period of 9 years (Lemogne et al. 2011). A 
more recent study on more than 1,000,000 participants reported that reduced cardiovascular fitness 
increases risk of suicide attempt or death by suicide by 79% over a 42 year follow-up period (Åberg 
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et al. 2013). Other studies further highlight a role for vagally mediated cardiovascular function in 
stress resilience (Hanson et al. 2013; Oldehinkel et al. 2008).  
The serotonin (5-HT) system has been associated with impulsivity (Depue and Spoont 1986; 
Robbins and Crockett 2009), aggression (Carrillo et al. 2009) and suicide (Mann 2003; Mann 
1998), and is a major target for the treatment of depression. The 5-HT system also plays a key role 
in regulating and maintaining cardiovascular function (Côté et al. 2004). Critically, acute 
manipulation of the 5-HT system  has demonstrable effects on the cardiovascular system and 
impulsivity (Booij et al. 2006; Kemp and Nathan 2004), providing a useful model to understand the 
mood disorders and early effects of treatment. While researchers (Straneva-Meuse 2004) have 
proposed that SSRI antidepressants exert their benefits through direct action on the biological 
substrates of the stress response – including a blunting of blood pressure, myocardial responses, and 
cortisol reactivity under stress – other research indicates that they may also have adverse 
cardiovascular effects, including reduced parasympathetic nervous system activity (Licht et al. 
2010). The increased suicidality in adolescents and young adults during the early treatment phase 
(Barbui et al. 2009; Gibbons et al. 2012; Hammad et al. 2006a; Stone et al. 2009a) suggests that 
these individuals may not benefit from the anxiolytic effects of SSRI antidepressants. There is 
substantial remodeling and maturation of the neurotransmitter systems – including 5-HT – during 
adolescence and into adulthood that may impact on the beneficial effects of antidepressants (Crews 
et al. 2007; Davey et al. 2008). Experimental animal research has shown that adolescent rats treated 
with paroxetine do not display the expected antidepressant effects on the forced swim test (FST) 
(Karanges et al. 2011). Furthermore, this study reported that two of the paroxetine-treated 
adolescents died unexpectedly after the FST suggesting a compromised response to physical stress 
(Karanges et al. 2011) (see also Karanges and McGregor 2011a for review). In an extension of this 
earlier study, we found (Karanges et al. 2013) that paroxetine-treated adolescent rats display a 
profile of hippocampal protein expression implicated in apoptosis, oxidative stress and 
monoaminergic neurotransmission. These findings provide experimental support for the 
epidemiological studies reporting ‘paradoxical’ antidepressant responses to SSRI treatment in 
young persons.  
Here we examine the impact of acute escitalopram administration on HR and HRV under 
resting state and stress, and determine whether age moderates this effect. We wanted to determine 
whether escitalopram adversely impacts on cardiovascular function in late adolescence and young 
adulthood (participants aged under 25 years) – a finding that would support previous research 
indicating adverse effects of antidepressants in youth (Barbui et al. 2009; Hammad et al. 2006a; 
Stone et al. 2009a). Alternatively, participants in late adolescence and young adulthood may simply 
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not experience the beneficial anti-panic properties that have been reported for escitlaopram (Hogg 
et al. 2006), a finding that would instead support the conclusions drawn by Gibbons and colleagues 
(Gibbons et al. 2012). The following hypotheses were made: (1) HR and HRV will increase and 
decrease under stress, respectively (main effect of task); (2) these responses will be attenuated by 
acute escitalopram treatment (main effect of treatment); and, (3) these responses will be moderated 
by age (interaction effects with task and treatment). We did not expect escitalopram to have 
favorable effects on vagally mediated cardiovascular function in the younger age group. 
 
Methods 
Subjects  
Forty-four female participants completed the experiment (Fig 1). Sample size represents a 
good balance of improved statistical power over prior studies – studies on healthy participants with 
between-subject experimental designs have generally reported on samples with less than 20 
participants (e.g. (Booij et al. 2006; Pohl et al. 2003)) – and ethical considerations relating to 
administration of antidepressants to young healthy participants. All participants provided informed 
consent in accordance with National Health and Medical Research Council (NHMRC) guidelines. 
This study was registered with the Australian and New Zealand Clinical Trials Registry (ANZCTR; 
ACTRN12611000719932) and was conducted at the CADE Clinic, a research unit in the Discipline 
of Psychiatry at Royal North Shore Hospital, Australia. Recruitment began in July 2011 and 
concluded July 2012. No changes in eligibility criteria were applied throughout the study. Exclusion 
criteria were as follows: age <18 or >50 years, history of psychiatric illness or antidepressant use, 
mild to severe depression or anxiety symptoms assessed using the 9-item depression module Patient 
Health Questionnaire (PHQ-9) and the 7-item generalized anxiety scale (GAD-7) (Kroenke et al. 
2001; Spitzer et al. 2006), use of medications which interact with escitalopram (minimum one 
month medication free was acceptable), alcohol use disorders or regular illicit drug use, serious 
medical conditions, neurological disorders, brain injury, loss of consciousness for more than five 
minutes, history of stroke, or pregnancy (tested at each session). Although important to investigate 
effects in participants younger than 18, we excluded these participants from the current study for 
ethical reasons. 
Experimental Design  
The present study employed a double blind, randomized, placebo-controlled, crossover, 
mixed experimental study with age as a between-subjects factor (under 25 years of age versus those 
25 years of age and over), while treatment and task were within-subjects factors. The age of 25 was 
selected as a cut-off because it is consistent with: 1) issued US Food and Drug Administration 
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(FDA) issued black box warnings on treatment-emergent suicidality in young adults under the age 
of 25, 2) meta-analyses supporting the FDA’s decision (Hammad et al. 2006b) and others since 
(Barbui et al. 2009; Stone et al. 2009b), and 3) neuroimaging evidence indicating that the PFC 
continues to mature up into early adulthood (Casey et al. 2008).  
An independent statistician generated the randomization list using standard software, and a 
pharmacist dispensed treatment in labeled containers in accordance with this list. Everyone 
involved in the study (researchers, participants, and clinicians) were blinded to the treatment 
condition until all assessments were completed. Participants were randomized to treatment order, 
and administered either a saccharin placebo or 20 mg of escitalopram on their first visit and the 
alternate treatment on their second visit. The pharmacokinetic profiles of escitalopram do not differ 
between adolescents and young adults indicating that dosage adjustment according to age is not 
required (Rao 2007). A one-week interval separated visits in order to ensure sufficient washout of at 
least 5 half-lives (Anonymous 2012; Sogaard 2005). Participants were administered twice the 
recommended starting dose (Anonymous 2012) to maximize receptor occupancy (Kasper et al. 
2009).  
HRV data was collected at the same time of day for both visits, to control for circadian 
changes in HR. Participants abstained from caffeine on the morning of the experiment to minimize 
cross-session changes in heart rate and blood pressure. Upon arrival at each session, participants 
completed pregnancy tests and provided saliva samples (1 mL) in order to test for progesterone and 
estradiol concentration (see supplemental information). After treatment administration, participants 
waited three hours before psychophysiological recordings began to allow escitalopram to reach 
expected peak blood plasma levels (tmax = 3.0 ± 1.5 hours; (Sogaard 2005)). A standardized snack 
was provided one and a half hours after treatment administration in order to control for changes in 
autonomic balance arising as a result of hunger and food intake. In order to examine the potential 
impact of treatment unblinding at each session, participants reported whether they experienced side 
effects and guessed their treatment condition (see supplemental information). 
HR and HF HRV (normalized units, n.u.) (0.15–0.40 Hz) recordings were made under two 
conditions: (1) a 5-minute resting state and (2) a 5-minute social stress task, using a Polar RS800CX 
heart rate monitor. These devices have excellent reliability and validity – in comparison to the 
electrocardiogram (ECG) – especially when data is collected from young, healthy individuals in a 
supine position and analysis is conducted on normalized values (Gamelin et al. 2006; Weippert et al. 
2010) (see also Quintana et al. 2012), as was done for the current study.	 This device is wirelessly 
connected to an electrode strap, wetted with saline solution (0.9% NaCl; to simulate sweat and 
ensure conductivity) and worn just beneath the chest. For the resting state recording, participants 
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were instructed to breathe normally, remain still and silent, and keep their eyes open in a seated 
position. The serial subtraction mental arithmetic component of the Trier Social Stress Test 
(Kirschbaum et al. 1993) was used for the stress condition, since it has been shown to reliably 
increase biomarkers of stress (Kirschbaum et al. 1993). The experimenter was seated in close 
proximity to the participant and acted in a formal manner, in order to further increase stress and 
social pressure.  
 
Data Analysis 
All HR and HF HRV data was extracted and manually inspected on Polar ProTrainer 5 
software prior to analysis. Data quality was excellent, consistent with recordings under stationary 
conditions. Data was analyzed using Kubios software (available at: http://kubios.uku.fi). After 
applying a medium-level artifact correction to all data files, the average HR (beats/minute; BPM) 
and HF HRV (normalized units, n.u.) (0.15–0.40 Hz) over each treatment and task condition was 
calculated. Two analyses of variance (ANOVAs) were performed including one for HR and another 
for HF HRV variables to determine the presence of a three-way interaction (Task, Treatment, Age 
Group). A factor of “treatment order” was not included in statistical analysis; order effects are rare, 
are generally underpowered even when an appreciable effect is present and sufficient drug washout 
ameliorates such effects (Mills et al. 2009; Senn 1994; Senn et al. 2004). Cohen’s d effect size 
statistics were calculated for each pairwise comparison.  Cohen’s guidelines (Cohen 1992; Cohen 
1988) identify 0.2, 0.5, and 0.8 as small, medium and large effects, respectively. Eta-squared (η2) 
was reported for ANOVA effects as an indicator of effect size (small = .01 medium = .06, large = 
.14; (Cohen 1992; Cohen 1988)). 
 
Results 
Participant Characteristics 
 No differences were observed between age groups on any of the following variables: 
ethnicity, BMI, hormonal contraceptive use, menstrual phase in either the placebo and drug 
conditions, experience of side effects, correct treatment condition guessing, alcohol consumption, 
smoking status, MDD or GAD symptoms, overall change in state anxiety as measured using the 
STAI, or time spent performing vigorous physical activity (Table 1). Years of education and time 
spent sedentary in the past week were significantly greater in the 25 years and over group relative to 
those under the age of 25.  
 
Examining the Impact of Potential Covariates 
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The impact of state anxiety, time spent sedentary and time spent performing vigorous 
activity – factors associated with current cardiac health and stress reactivity – on HR and HF HRV 
was examined. For HR, significant findings were observed for time spent sedentary (F[1, 35] = 
5.777, p = .022, η2 = .180) and the interaction between state anxiety and sedentary activity (F[1, 35] 
= 4.533, p = .040, η2 = .115) were observed. These findings indicate that between-subjects factors 
associated with cardiac health and functioning explain some of the variance in HR. For HF HRV, a 
significant interaction between state anxiety and vigorous activity was observed, F(1, 35) = 4.273, p 
= .046, η2 = .109, again indicating that some variance in the HF measure is explained by factors 
associated with current cardiac health and functioning. No significant effects of other between-
subjects factors – including the experience of side effects and correct treatment condition guessing 
– on HR or HF HRV variables were observed. State anxiety, time spent sedentary and performing 
vigorous activity were therefore entered as covariates in analyses and these results are reported 
below. (Non-covaried findings are reported in supplementary information). It is important to note 
that key findings were obtained with and without use of covariates.  
 
Within Subjects Factors  
Main Effect of Task 
 For HR, a significant main effect of task condition was observed, F(1, 35) = 37.763, p < 
.001, η2 = .519. In comparison to the rest condition, follow-up analysis revealed that HR was 
significantly increased under stress, t(35) = 13.241, p < .001, d = 4.476. This main effect of task 
was also observed in the HF HRV results, F(1, 35) = 11.496, p = .002, η2 = .247. In comparison to 
the rest condition, follow-up analysis revealed that HF was significantly reduced under stress, t(35) 
= 8.564, p < .001, d = 2.895. (Fig 2, row 1). In summary, HR increased and HRV decreased under 
stress, findings associated with a large effect size. 
 
Main Effect of Treatment  
For HR, a significant main effect of treatment condition was found, F(1, 35) = 4.865, p = 
.034, η2 = .122. Follow-up analysis revealed that HR was significantly reduced under escitalopram 
in comparison to placebo, t(35) = 2.038, p < .001, d = 1.598. For HRV, a main effect of treatment 
condition was also observed, F(1, 35) = 4.514, p = .041, η2 = .114. Follow-up analysis revealed that 
HF was greater under escitalopram than placebo, t(35) = 2.038, p = .049, d = 0.689 (Fig 2, row 2). 
In summary, HR reduced and HRV increased with escitalopram treatment, findings associated with 
a moderate (HRV) to large (HR) effect size. 
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Treatment × Task Interaction  
For HR, escitalopram decreased HR in the rest (t[35] = 3.271, p = .002, d = 1.106) and stress 
conditions (t[35] = 4.757, p < .001, d = 1.608) (Fig 2, row 3, column 1), however, a significant 
treatment × task interaction effect was not observed. For HF HRV, a significant interaction effect of 
treatment × task condition was observed, F(1, 35) = 7.289, p = .011, η2 = .172. Follow-up analyses 
revealed that HF was significantly greater under escitalopram during the rest condition, t(35) = 
2.230, p = .032, d = 0.754. (Fig 2, row 3, column 2). In summary, treatment with escitalopram 
decreased HR in the rest and stress conditions, while HF HRV was increased during the rest 
condition only, reflecting the difficulty of increasing parasympathetic function during stress. All 
findings were associated with a large effect size. 
 
Interactions of Within Subjects and Between Subjects Factors ii 
Treatment × Age Group Interaction  
No significant treatment × age group interaction effects were observed for either HR or HF 
HRV. 
 
Task x Age Interaction 
No significant task × age group interaction effects were observed for either HR or HF HRV. 
 
Treatment × Task × Age Group Interaction  
A treatment × task × age group interaction for HR was observed at trend levels, F(1, 35) = 
3.778, p = .060, η2 = .097. Follow-up analyses revealed that, for those aged 25 years and over, HR 
during the rest condition was significantly decreased under escitalopram when compared with 
placebo, t[35] = 2.379, p = .021, d = 0.804 (Fig 3, row 1, column 1). A more pronounced effect was 
found during the stress condition, such that those aged 25 years and over displayed significantly 
decreased HR under escitalopram when compared with placebo t[35] = 4.471, p < .001, d = 1.512 
(Fig 3, row 1, column 1). While these findings in those aged 35 years and over were associated with 
a large effect size, no significant effects were observed for those aged under 25 years (Fig 3, rows 1 
and 2, column 1). Complementing our HR findings from ANOVA, regression analysis revealed 
more attenuation of stress by escitalopram with increasing age, (p=0.045, r2=0.092), a finding 
associated with a moderate effect size (Fig 4). For HF HRV, a significant interaction effect of 
treatment × task × age group was also observed, F(1, 35) = 6.314, p = .017, η2 = .153. In 
comparison to placebo, follow-up analysis revealed that HF HRV was greater under escitalopram 
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during the rest condition for those only over the age of 25 years (t[35] = 2.890, p = .007, d = 0.977; 
see Fig 3, row 1, column 2). No such change was observed for those under the age of 25 years.  
 
Discussion 
Research on vagally mediated cardiovascular effects of antidepressants may have important 
implications for better understanding age-related treatment-emergent side effects. Confirming our 
hypotheses, we show here that age moderates acute treatment effects on HR and HRV – key 
measures of cardiovascular function under tonic inhibitory control of the vagus nerve. Key findings 
from the present study were that (1) HR was increased and HRV decreased under stress (main 
effect of task), providing an important validation of our stressor, 2) HR was decreased and HRV 
increased under escitalopram (main effect of drug), indicating that acute administration of SSRIs 
have beneficial inhibitory effects on cardiovascular function, 3) HR of participants aged 25 years 
and over was decreased by escitalopram and this effect was most pronounced during stress 
(treatment x task x age interaction), and 4) HF HRV was increased under escitalopram during rest 
only (treatment x task interaction), reflecting the difficulty of increasing parasympathetic function 
under stress. This latter effect was significant only in those aged 25 years and over (treatment x task 
x age interaction). Importantly, task effects are not dependent on age (no interaction between task 
and age was observed) highlighting that maturational differences relate to the capacity of treatment 
to impact on cardiovascular responses to stress, rather than differential age-related responses to 
task, subsequently impacting on treatment. These findings provide a potential psychophysiological 
explanation for recent findings (Gibbons et al. 2012) indicating that unlike adults 25 years of age 
and over, antidepressant treatment is not successful in ameliorating reductions in vagally mediated 
cardiovascular function in those aged under 25 years (Gibbons et al. 2012). As vagally mediated 
cardiovascular function plays an important role in psychological flexibility (Kashdan and 
Rottenberg 2010), stress resilience (Oldehinkel et al. 2008; Thayer et al. 2009) and even, suicidality 
(Åberg et al. 2013; Lemogne et al. 2011), our findings have important implications for the capacity 
of escitalopram to modulate responses to stress in a flexible and adaptive manner in adolescents and 
young adults.  
We suggest that maturation of the PFC may underpin the differential attenuation of 
cardiovascular responses to stress following administration of escitalopram, findings reported here. 
While cortical changes do occur in childhood and adolescence – particularly in the parietal cortex 
(Cohen et al. 1992) –  research indicates that frontal regions develop well into the 20’s (23-30 
years) relative to adolescents (12-16 year olds) (Sowell et al. 1999). Adolescence and young 
adulthood is characterized by PFC immaturity and insufficient top-down control of subcortical 
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structures (Casey et al. 2008; Sowell et al. 1999). These changes may be underpinned by decreases 
in gray matter paralleled by increases in myelination (Benes et al. 1994; Yakovlev and Lecours 
1967). Although the serotonin system develops to near maturity in the first years of life, 
maturational changes continue to occur throughout adolescence and into adulthood (Crews et al. 
2007; Karanges and McGregor 2011b). The adolescent brain is characterized by increased serotonin 
levels and 5-HT1A and 5-HT2A receptor densities (Crews et al. 2007; Murrin et al. 2007), but 
lower 5-HTT density and serotonin turnover (Crews et al. 2007; Moll et al. 2000). The serotonin 
system is diverse and neurochemically complex, however, it is understood to play a critical 
inhibitory role in the PFC (Fuster 2008; Puig and Gulledge 2011) and is implicated in a variety of 
behaviours including impulsivity (Depue and Spoont 1986; Robbins and Crockett 2009), aggression 
(Carrillo et al. 2009) and suicide (Mann 2003; Mann 1998). Maturation of the PFC and the 
serotonergic system will therefore limit the beneficial effects of escitalopram on vagally mediated 
cardiovascular function. Our findings indicate that escitalopram does not improve the capacity for 
flexible and adaptive responding to stress in adolescents and young adults, unlike that for those 
aged over 25 years of age. The failure of escitalopram to increase cardiac vagal control in 
participants under the age of 25 suggests that ongoing neurochemical, functional and structural 
maturation in young adults may limit the beneficial effects of escitalopram. We suggest that 
antidepressants may have greater impact on vagally mediated cardiovascular function in those 25 
years of age and older, because of their action on a more developed PFC – including 5-HT 
pathways – and downstream parasympathetic inhibition of cardiovascular responses to stress. 
Further studies are required to further understand the mechanisms underpinning paradoxical 
antidepressant responses in adolescents and young adults.  
A limitation of the present study was potential unblinding of treatment – participants 
correctly guessed treatment condition above chance levels when they experienced side effects (see 
supplementary information), consistent with those typically experienced with escitalopram 
(Cipriani et al. 2009). However, guessing and side effects did not differentially affect HR or HF 
HRV (supplementary information), indicating that these factors are unlikely to have contributed and 
confounded the results of the present study. Nevertheless, future research may consider employing 
an active placebo condition (specifically, a treatment that replicates the side effects of the 
antidepressant of interest) in order to control for the potential impact of side effects on stress 
reactivity. Another possible limitation of the present study was that a female-only sample was 
employed, however differential impacts of hormonal or menstrual status on HR or HRV measures 
were not observed (see supplemental information). Female participants were selected for study as 
they are more responsive to SSRI treatment (Khan et al. 2005), have greater physiological 
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responses to stress induction (Li et al. 2009) and are twice as likely to be diagnosed with affective 
disorders (Altemus 2006). It is also important to acknowledge that findings reported here are based 
on acute administration of escitalopram, while epidemiological findings associated with suicidality 
in adolescents and young adults are associated with sub-chronic treatment (i.e. the early activating 
effects of antidepressant treatment). However, early psychophysiological changes may precede any 
overt, observable change in behavior (Kemp et al. 2004; Kemp and Nathan 2004), and these early 
changes provide a platform on which later changes in behavior are based (Harmer et al. 2009). 
Finally, while we focus on a healthy participant sample, we avoid the many confounds associated 
with studies on patients including non-randomized-controlled designs, difficulty in distinguishing 
between the effects of medication versus illness severity, cardiovascular health, sex, and hormonal 
status.  
In conclusion, the present study found for the first time that acute administration of 
escitalopram does not attenuate cardiovascular responses to stress in those under 25 years of age, 
providing a potential psychophysiological mechanism for better understanding findings on age-
related treatment-emergent suicidality in epidemiological studies (Gibbons et al. 2012). Future 
epidemiological research on clinical populations should consider incorporating measures of cardiac 
vagal control to further examine whether age- and treatment-emergent suicidality are associated 
with a lack of cardiac vagal control. 
 
Supplementary information is available at the Psychopharmacology website. 
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Table 1 
Participant demographics 
 Under 25s  
(n = 26) 
 25 and over  
(n = 18) 
Group 
Differences 
Age  
(years; SD) 
20.54 
(2.01) 
 
29.50 
(6.46) 
t(42) = 6.66 
p < .001 
Education  
(years; SD) 
14.88 
(1.66) 
 
19.17 
(2.12) 
t(42) = 7.51 
p < .001 
Ethnicity  
(C/NC) 
2/24  0/18 
χ2(1) = 1.451 
p = .228 
BMI  
(kg/m2; SD) 
22.79 
(3.46) 
 
22.91 
(2.38) 
t(42) = 0.13 
p = .896 
Hormonal contraceptive use 
(Y/N) 
12/14  9/9 
χ2(1) = 0.063 
p = .802 
Menstrual phase Placebo 
(F/M/L) 
11/7/8  5/7/6 
χ2(2) = 1.118 
p = .572 
Menstrual phase Drug 
(F/M/L) 
11/7/8  5/9/4 
χ2(2) = 2.460 
p = .292 
Side effects 
(Y/N) 
12/14  9/9 
χ2(1) = 0.063 
p = .802 
Correct treatment guess 
(Y/N) 
7/19  6/12 
χ2(1) = 0.210 
p = .647 
AUDIT Total 
(SD) 
7.54 
(5.57) 
 
5.11 
(3.16) 
t(42) = 1.69 
p = .103 
Smoking  
(Y/N) 
0/26  0/18 - 
PHQ-9  
(SD) 
1.85 
(1.43) 
 
1.11 
(1.02) 
t(42) = 1.89 
p = .069 
GAD-7  
(SD) 
1.31 
(1.26) 
 
0.83 
(0.99) 
t(42) = 1.34 
p = .188 
STAI State overall change 
(SD) 
2.27 
(9.41) 
 
5.17 
(9.17) 
t(42) = 1.02 
p = .188 
IPAQ Sedentary  
(mins/week; SD) 
302.31 
(132.80) 
 
440.00 
(169.39) 
t(42) = 3.02 
p = .004 
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IPAQ Vigorous 
(mins/week; SD) 
106.15 
(120.38) 
 
166.67 
(107.54) 
t(42) = 1.711 
p = .094 
     
Note. SD = standard deviation; C/NC = Caucasian/Non-Caucasian; Y/N = Yes/No; F/M/L = 
Follicular/Mid-luteal-Luteal; PHQ-9 = Patient Health Questionnaire; GAD-7 = Generalized 
Anxiety Disorder questionnaire; STAI State = State-Trait Anxiety Inventory for Adults State; IPAQ 
= International Physical Activity Questionnaire.   
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Captions: 
 
Figure 1. Flowchart depicting participant attrition from the experiment and the reasons and various 
stages at which they were excluded. 
 
Figure 2. Main effects of task (row 1), treatment (row 2) and their interaction (row 3) for HR 
(column 1) and HF HRV (column 2). Heart rate increases under stress (main effect of task), 
decreases during drug treatment (main effect of treatment) and decreases are greatest under stress, 
although this interaction effect was not significant. Heart rate variability decreases under stress 
(main effect of task), increases during drug treatment (main effect of treatment) and increases are 
greatest under rest (interaction effect). The lack of a significant effect for heart rate variability under 
stress reflects the difficulty of increasing parasympathetic function under stress. 
 
Figure 3. Moderation of treatment effects by age during resting state (row 1) and stress (row 2) for 
HR (column 1) and HF HRV (column 2). While effects are significant for those aged 25 and over – 
findings associated with a large effect size – they are not significant for those under 25.  
 
Figure 4. Individual participant data relating to attenuation of change in HR during stress with 
escitalopram. The attenuation of change in HR during stress with escitalopram was calculated using 
the following formula: (HR_rest_drug - HR_stress_drug) - (HR_rest_placebo - 
HR_stress_placebo). A positive score on this measure represents greater attenuation of the stress 
with escitalopram (i.e. larger the score, the more attenuation).  
  
Kemp and colleagues, Escitalopram, Stress and Age      18 
 
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Participant attrition from the experiment and the reasons and various stages at which they 
were excluded (according to CONSORT guidelines). 
  
Expressions of interest (n=369)		
No contact after email reply (n= 141) 
No longer interested (n= 5) 
Could not attend sessions (n= 47) 
Not Eligible (n=109) 
    Contraindications for escitalopram (n= 28) 
    Psychiatric history (n=20) 
    Males (n= 9) 
    Medical conditions (n=7) 
    Other  (n=45) 
Tested on both sessions (n= 44) 
Data Collection &  
Analysis 
Eligibility phone screens (n=67) 
Enrollment &  
Allocation 
Excluded (n=7) 
   Reported psychiatric history (n=2) 
   Reported neurological history (n=2) 
   High GAD-7 score (n=1)  
   Other (n = 2)    
Could not attend sessions (n = 4) 
Cancelled prior to first session (n=3) 
(remainder are new recruits [n = 4]) 
Randomized to treatment (n=50) 
Assignment to escitalopram first 
(n=25) 
Assignment to Placebo first (n=25)  
 
Recruitment 
Exclusions 
Lost to second session for which treatments 
were reallocated to new recruits (n=4) 
Lost to second session for which treatments 
could not be reallocated (n=2) 
Analysed (n= 44) 
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Fig 3  
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